An in vivo avian model of human melanoma to perform rapid and robust preclinical studies - CRCL-Plasticité tumorale dans le mélanome Accéder directement au contenu
Article Dans Une Revue EMBO Molecular Medicine Année : 2023

An in vivo avian model of human melanoma to perform rapid and robust preclinical studies

Loraine Jarrosson
Romain Teinturier

Résumé

Metastatic melanoma patients carrying a BRAFV600 mutation can be treated with a combination of BRAF and MEK inhibitors (BRAFi/MEKi), but innate and acquired resistance invariably occurs. Predicting patient response to targeted therapies is crucial to guide clinical decision. We describe here the development of a highly efficient patient-derived xenograft model adapted to patient melanoma biopsies, using the avian embryo as a host (AVI-PDXTM ). In this in vivo paradigm, we depict a fast and reproducible tumor engraftment of patient samples within the embryonic skin, preserving key molecular and phenotypic features. We show that sensitivity and resistance to BRAFi/MEKi can be reliably modeled in these AVI-PDXTM , as well as synergies with other drugs. We further provide proof-of-concept that the AVI-PDXTM models the diversity of responses of melanoma patients to BRAFi/MEKi, within days, hence positioning it as a valuable tool for the design of personalized medicine assays and for the evaluation of novel combination strategies.

Domaines

Cancer
Fichier principal
Vignette du fichier
EMMM-15-e16629.pdf (2.26 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04066053 , version 1 (13-06-2023)

Identifiants

Citer

Loraine Jarrosson, Stéphane Dalle, Clélia Costechareyre, Yaqi Tang, Maxime Grimont, et al.. An in vivo avian model of human melanoma to perform rapid and robust preclinical studies. EMBO Molecular Medicine, 2023, 15 (3), ⟨10.15252/emmm.202216629⟩. ⟨hal-04066053⟩
30 Consultations
14 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More